article
4 September 2018 | By Arie Reijerkerk, Farbod Famili, Mieke Doornbos, Stefan Braam
Effective drug discovery and development relies largely on the availability of predictive pre-clinical model systems; the absence of which has contributed to late-stage drug failures and high expenditures. New industry acceptance of human induced pluripotent stem cell (hiPSC)-derived cardiomyocyte assay systems for regulatory safety pharmacology is now resulting in broad…